{"prompt": "['OSTPDL1', 'Page 34 of 60', 'Repeat labs in 1 to 3', 'weeks', 'MRI in 1 month', 'Suspicion of adrenal crisis', 'Delay or discontinue avelumab therapy', '(for example, severe', 'Rule out sepsis', 'dehydration, hypotension,', 'Stress dose of IV steroids with mineralocorticoid', 'shock out of proportion to', 'activity', 'current illness)', 'IV fluids', 'Consult endocrinologist', 'If adrenal crisis ruled out, then treat as above for', 'symptomatic endocrinopathy', 'Cardiac irAEs', 'Myocarditis', 'Management', 'Follow-up', 'New onset of cardiac', 'Withhold avelumab', 'If symptoms improve and', 'signs or symptoms and /', 'therapy', 'immune-mediated', 'or new laboratory cardiac', 'etiology is ruled out, re-', 'biomarker elevations (e.g.', 'Hospitalize. In the', 'start avelumab therapy.', 'troponin, CK-MB, BNP) or', 'presence of life', 'cardiac imaging', 'threatening cardiac', 'If symptoms do not', 'abnormalities suggestive', 'decompensation, consider', 'improve/worsen, viral', 'of myocarditis.', 'transfer to a facility', 'myocarditis is excluded,', 'experienced in advanced', 'and immune-mediated', 'heart failure and', 'etiology is suspected or', 'arrhythmia management.', 'confirmed following', 'cardiology consult,', 'Cardiology consult to', 'manage as immune- -', 'establish etiology and', 'mediated myocarditis.', 'rule-out immune-', 'mediated myocarditis.', 'Guideline based', 'supportive treatment as', 'appropriate per cardiology', 'consult.*', 'Consider myocardial', 'biopsy if recommended', 'per cardiology consult.', 'Immune-mediated', 'Permanently discontinue', 'Once improving, taper', 'myocarditis', 'avelumab.', 'steroids over at least 1', 'month and add', 'Guideline based', 'prophylactic antibiotics', 'supportive treatment as', 'for opportunistic', 'appropriate per cardiology', 'infections.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-ARB RPPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 35 of 60', 'consult.*', 'If no improvement or', 'worsening, consider', 'Methylprednisolone 1-2', 'additional', 'mg/kg/day.', 'immunosuppressions (e.g.', 'azathioprine, cyclosporine', 'A)', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-3018 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 36 of 60', '5.4 Autoimmune or Immune System Disorders Affecting Other', 'Organ Systems', 'Patients experiencing symptoms that may be associated with', 'autoimmune or immune-mediated adverse events possibly, probably or', 'definitely related to protocol therapy should be evaluated and monitored', 'closely. These may include but are not limited to pneumonitis, sarcoid- -', 'like granuloma and neurologic events including hypophysitis,', 'encephalitis, aseptic meningitis, and cranial neuropathy especially', 'seventh cranial nerve (CNVII) palsy. Consideration should be given to', 'subspecialty consultation particularly if systemic immune suppression is', 'considered.', '5.5', 'Central Venous Catheter', 'While not required for the purposes of this study, the insertion of a', 'central venous catheter/line (CVL) is recommended for all patients for', 'intravenous (IV) administration of study drug as well as other supportive', 'medications and laboratory blood draws. Placement of the CVL may be', 'performed by the treating institution based on local guidelines for best', 'medical practice.', '5.6', 'Concomitant Therapy', 'Concurrent cancer therapy, including chemotherapy, radiation therapy,', 'immunotherapy or biologic therapy may NOT be administered to patients', 'receiving study drug. If these treatments are administered the patient will', 'be removed from protocol therapy. Immunotherapy and', 'immunosuppressive drugs (i.e., systemic corticosteroids except for short', 'term treatment of allergic reactions or for the treatment of immune-', 'related adverse events) should not be administered during the study. For', 'patients with adrenal insufficiency, physiological dosing of steroids is', 'acceptable. Herbal remedies with immunostimulating properties (e.g.,', 'mistletoe extract) or interference with major organ function (e.g.,', 'hypericin) should not be used during the study. Vaccines should not be', 'administered during treatment, with the exception of administration of', 'the inactive influenza vaccine. No other investigational agents may be', 'given while the patient is on study.', '6.0', 'DRUG INFORMATION', '6.1', 'Avelumab (MSB0010718C, anti-PD-L1)', 'Source and pharmacology: Avelumab is a fully human antibody of the', 'immunoglobulin (lgG) 1 isotype that specifically targets and blocks PD-', 'L1.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}